Subjective cognitive decline (terminological and diagnostic boundaries)

Subjective cognitive decline (terminological and diagnostic boundaries)

 

Authors

 

A.P. Sidenkova

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation

L.T. Baranskaya

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation

E.I. Babushkina

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation

I.V. Sokolova

Federal State Budgetary Educational Institution of Higher Education “Ural State Medical University” of the Ministry of Health of the Russian Federation, Yekaterinburg, Russian Federation

 

https://doi.org/10.26617/1810-3111-2023-3(120)-70-79

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2023; 3 (120):  70-79.

 

Abstract

This article provides an overview of modern scientific domestic and foreign publications devoted to the phenomenon of subjective cognitive decline. Subjective cognitive decline is considered by the authors of this work as a transitional syndrome, borderline between the age-related cognitive norm and phenomenologically manifested cognitive disorder. A discussion of the issues of terminological and diagnostic boundaries, the dynamics of subjective cognitive decline determines the possibility of variable prediction of the course of a neurodegenerative disease, taking into account the pathogenic mechanisms of the disease and the protective properties of the cerebral-cognitive reserve, which is prospective for future research on the issue of cognitive disorders. Objective: to systematize modern data in the field of research on subjective cognitive decline, clarify the terminological and diagnostic boundaries of this phenomenon, determine its place in the continuum of cognitive states during mental aging from age-related cognitive norms to cognitive disorders. Materials and Methods: scientific publications on the topic of work, selected from open access publications. A general scientific method was used: analysis of modern scientific domestic and foreign literature on the research problem, generalization, comparison, systematization of theoretical data on the preclinical stage of Alzheimer's disease. Information search was carried out using keywords: subjective cognitive decline, cognitive reserve.

 

Keywords: aging, neurodegeneration, central nervous system, Alzheimer's disease, subjective cognitive decline, cognitive reserve.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials  

For citation: Sidenkova A.P., Baranskaya L.T., Babushkina E.I., Sokolova I.V. Subjective cognitive decline (terminological and diagnostic boundaries). Siberian Herald of Psychiatry and Addiction Psychiatry.2023; 3 (120): 70-79. https://doi.org/10.26617/1810-3111-2023-3(120)-70-79

 

REFERENCES

  1. Duyckaerts C, Braak H, Brion JP, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T. PART is part of Alzheimer disease. Acta Neuropathol. 2015 May;129(5):749-56. doi: 10.1007/s00401-015-1390-7. Epub 2015 Jan 28. PMID: 25628035; PMCID: PMC4405349.
  2. Ferrer I. Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective. Free Neuropathol. 2022 Jul 8;3:3-17. doi: 10.17879/freeneuropathology-2022-3806. PMID: 37284149; PMCID: PMC10209894.
  3. Avila J, Perry G. A Multilevel View of the Development of Alzheimer's Disease. Neuroscience. 2021 Mar 1;457:283-293. doi: 10.1016/j.neuroscience.2020.11.015. Epub 2020 Nov 24. PMID: 33246061.
  4. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002. PMID: 27012484; PMCID: PMC6417794.
  5. Ávila-Villanueva M, Dolado AM, Fernández-Blázquez M. How to Prevent and/or Revert Alzheimer's Disease Continuum During Preclinical Phases. J Alzheimers Dis Rep. 2023 Jun 1;7(1):505-512. doi: 10.3233/ADR220100. PMID: 37313496; PMCID: PMC10259072.
  6. Lista S, Dubois B, Hampel H. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies. J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3. PMID: 25651440.
  7. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21. PMID: 21514248; PMCID: PMC3220946.
  8. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct;72(4):578-86. doi: 10.1002/ana.23650. PMID: 23109153; PMCID: PMC3786871.
  9. Qiu Y, Li L, Zhou TY, Lu W; Alzheimer's Disease Neuroimaging Initiative. Alzheimer's disease progression model based on integrated biomarkers and clinical measures. Acta Pharmacol Sin. 2014 Sep;35(9):1111-20. doi: 10.1038/aps.2014.57. Epub 2014 Aug 4. PMID: 25088003; PMCID: PMC4155529.
  10. Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR Jr, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI). APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec;11(12):1417-1429. doi: 10.1016/j.jalz.2015.03.003. Epub 2015 May 7. PMID: 25960448; PMCID: PMC4637003.
  11. Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, O'Brien RJ, Selnes OA, Albert MS; BIOCARD Research Team. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. JAMA Neurol. 2016 Jun 1;73(6):698-705. doi: 10.1001/jamaneurol.2016.0194. PMID: 27064267; PMCID: PMC5173327.
  12. Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative. Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Front Neurosci. 2017 May 17;11:281. doi: 10.3389/fnins.2017.00281. PMID: 28567001; PMCID: PMC5434146.
  13. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734-46. doi: 10.1016/S1474-4422(07)70178-3. PMID: 17616482.
  14. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757. PMID: 24849862.
  15. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group; Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668. PMID: 25988462; PMCID: PMC4486209.
  16. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris JC, Holtzman DM; Dominantly Inherited Alzheimer Network. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014 Mar 5;6(226):226ra30. doi: 10.1126/scitranslmed.3007901. PMID: 24598588; PMCID: PMC4038930.
  17. Martin SB, Smith CD, Collins HR, Schmitt FA, Gold BT. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiol Aging. 2010 Jul;31(7):1099-106. doi: 10.1016/j.neurobiolaging.2008.08.010. Epub 2008 Sep 21. PMID: 18809227; PMCID: PMC2873058.
  18. Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013 Sep 9;8(9):e74062. doi: 10.1371/journal.pone.0074062. PMID: 24040166; PMCID: PMC3767625.
  19. Caselli RJ, Chen K, Locke DE, Lee W, Roontiva A, Bandy D, Fleisher AS, Reiman EM. Subjective cognitive decline: self and informant comparisons. Alzheimers Dement. 2014 Jan;10(1):93-8. doi: 10.1016/j.jalz.2013.01.003. Epub 2013 Apr 3. PMID: 23562429; PMCID: PMC3732500.
  20. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr. 2008 Feb;20(1):1-16. doi: 10.1017/S1041610207006412. PMID: 18072981.
  21. Stewart R. Subjective cognitive impairment. Curr Opin Psychiatry. 2012 Nov;25(6):445-50. doi: 10.1097/YCO.0b013e3283586fd8. PMID: 23037961
  22. Jeste DV. Subjective cognitive complaints: what do they predict? Int Psychogeriatr. 2022 Dec;34(12):1005-1006. doi: 10.1017/S1041610222001077. PMID: 36484379
  23. Donix M, Seidlitz A, Buthut M, Löck S, Meissner G, Matthes C, Troost EGC, Baumann M, Raschke F, Linn J, Krause M. Subjective memory impairment in glioma patients with curative radiotherapy. Radiother Oncol. 2022 Jun;171:101-106. doi: 10.1016/j.radonc.2022.04.010. Epub 2022 Apr 18. PMID: 35447285
  24. Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, Wu P, Thana-Udom K, Ercoli LM, Siddarth P. A randomized double-blind placebo-controlled trial of combined escitalopram and memantine for older adults with major depression and subjective memory complaints. Am J Geriatr Psychiatry. 2020 Feb;28(2):178-190. doi: 10.1016/j.jagp.2019.08.011. Epub 2019 Aug 22. PMID: 31519517; PMCID: PMC6997044
  25. Smits LL, van Harten AC, Pijnenburg YA, Koedam EL, Bouwman FH, Sistermans N, Reuling IE, Prins ND, Lemstra AW, Scheltens P, van der Flier WM. Trajectories of cognitive decline in different types of dementia. Psychol Med. 2015 Apr;45(5):1051-9. doi: 10.1017/S0033291714002153. PMID: 25229325.
  26. Sidenkova AP. Characteristics of anxiety in patients of older age groups with different types of mild cognitive disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):45‑50. doi: 10.17116/jnevro201711711145-50(in Russian).
  27. Myakotnykh VS, Sidenkova AP, Borovkova TA, Berezina DA. Medical, psychological, social and gender aspects of aging in modern Russia. Advances in Gerontology. 2014;27(2):302-309 (in Russian).
  28. Sidenkova AP. Features of identification of mental disorders of later age. Russian Journal of Psychiatry. 2009;1:44-48 (in Russian).
  29. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. Annu Rev Clin Psychol. 2017 May 8;13:369-396. doi: 10.1146/annurev-clinpsy-032816-045136. PMID: 28482688.
  30. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3. PMID: 24798886; PMCID: PMC4317324.
  31. Abdelnour C, Agosta F, Bozzali M, Fougère B, Iwata A, Nilforooshan R, Takada LT, Viñuela F, Traber M. Perspectives and challenges in patient stratification in Alzheimer's disease. Alzheimers Res Ther. 2022 Aug 13;14(1):112. doi: 10.1186/s13195-022-01055-y. PMID: 35964143; PMCID: PMC9375274.
  32. Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013 Mar 5;2:356-65. doi: 10.1016/j.nicl.2013.02.006. PMID: 24179789; PMCID: PMC3777672.
  33. Ulbl J, Rakusa M. The importance of subjective cognitive decline recognition and the potential of molecular and neurophysiological biomarkers ‒ a systematic review. Int J Mol Sci. 2023 Jun 15;24(12):10158. doi: 10.3390/ijms241210158. PMID: 37373304; PMCID: PMC10299427.
  34. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; Subjective Cognitive Decline Initiative (SCD-I) Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012. Epub 2016 Nov 5. PMID: 27825022; PMCID: PMC5344703.
  35. Smid J, Studart-Neto A, César-Freitas KG, Dourado MCN, Kochhann R, Barbosa BJAP, Schilling LP, Balthazar MLF, Frota NAF, de Souza LC, Caramelli P, Bertolucci PHF, Chaves MLF, Brucki SMD, Nitrini R, Resende EPF, Vale FAC. Subjective cognitive decline, mild cognitive impairment, and dementia ‒ syndromic approach: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol. 2022 Nov 28;16(3 Suppl 1):1-24. doi: 10.1590/1980-5764-DN-2022-S101PT. PMID: 36533160; PMCID: PMC9745999.
  36. Mark RE, Brehmer Y. Preclinical Alzheimer's dementia: a useful concept or another dead end? Eur J Ageing. 2022 Oct 19;19(4):997-1004. doi: 10.1007/s10433-022-00735-w. PMID: 36506684; PMCID: PMC9729660.
  37. Jenkins A, Tree J, Tales A. Distinct Profile Differences in Subjective Cognitive Decline in the General Public Are Associated with Metacognition, Negative Affective Symptoms, Neuroticism, Stress, and Poor Quality of Life. J Alzheimers Dis. 2021;80(3):1231-1242. doi: 10.3233/JAD-200882. PMID: 33646150; PMCID: PMC8150446.
  38. Sidenkova AP. Dynamic analysis of socio-psychological factors of compliance with long-term antidementia therapy. Psychiatry. 2016;1(69):27-33 (in Russian).
  39. Serdyuk OV, Sidenkova AP, Khilyuk DA. Clinical and dynamic features and prognostic significance of non-cognitive psychopathological symptoms in mild cognitive decline syndrome. Psychiatry. 2021;19(2):17-28. DOI:10.30629/2618-6667-2021-19-2-17-28(in Russian).
  40. Kovtun OP, Sidenkova AP, Izmozherova NV, Vikhareva AA, Melnik AA, Rezaikin AV. The structure of adherence to drug therapy in elderly patients with mild cognitive decline and psychopathological symptoms. Kazan Medical Journal. 2022;103(1):44-53 (in Russian).
  41. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, Lautenschlager NT, Lenzo N, Martins RN, Maruff P, Masters C, Milner A, Pike K, Rowe C, Savage G, Szoeke C, Taddei K, Villemagne V, Woodward M, Ames D; AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009 Aug;21(4):672-87. doi: 10.1017/S1041610209009405. PMID: 19470201.
  42. Komalasari R, Mpofu E, Prybutok G, Ingman S. Daily living subjective cognitive decline indicators in older adults with depressive symptoms: a scoping review and categorization using classification of functioning, disability, and health (ICF). Healthcare (Basel). 2022 Aug 10;10(8):1508. doi: 10.3390/healthcare10081508. PMID: 36011165; PMCID: PMC9408360.
  43. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, Ewers M, Hampel H, Klöppel S, Rami L, Reisberg B, Saykin AJ, Sikkes S, Smart CM, Snitz BE, Sperling R, van der Flier WM, Wagner M, Jessen F; SCD-I Working Group. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017 Mar;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012. PMID: 27825022; PMCID: PMC5344703.
  44. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, Roberts RO, Geda YE, Swenson-Dravis DM, Boeve BF, Senjem ML, Vemuri P, Petersen RC, Jack CRJr. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012 Oct 9;79(15):1570-7. doi: 10.1212/WNL.0b013e31826e2696. PMID: 22972644; PMCID: PMC3475629.
  45. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014 Dec;130(6):439-51. doi: 10.1111/acps.12336. Epub 2014 Sep 13. PMID: 25219393.
  46. Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, Rainey-Smith S, Lautenschlager N, Rowe CC, Savage G, Villemagne VL, Ellis KA; AIBL study. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimers Dement. 2016 Jul;12(7):796-804. doi: 10.1016/j.jalz.2015.12.013. Epub 2016 Feb 4. PMID: 26852195.
  47. Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20. PMID: 24252258.
  48. Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Boeve BF, Petersen RC. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012 May 15;78(20):1576-82. doi: 10.1212/WNL.0b013e3182563bbe. Epub 2012 May 2. Erratum in: Neurology. 2017 Aug 29;89(9):980. PMID: 22551733; PMCID: PMC3348848.
  49. Bazarnyy VV, Sidenkova AP, Sosnin DYu. Lactoferrin in oral fluid in normal conditions and in Alzheimer's disease: laboratory and diagnostic aspects (literature review). Clinical Laboratory Diagnostics. 2022;67(4):207-212.doi: 10.51620/0869-2084-2022-67-4-207-212(in Russian).
  50. Bazarnyy VV, Mandra YuV, Sidenkova AP, Polushina LG, Maksimova AYu, Sementsova EA, Svetlakova EN, Nafetdinova NYu, Kotikova AYu. Age-related features of the buccal epithelium of practically healthy people. Clinical Laboratory Diagnostics. 2022;67(6):345-349. doi: 10.51620/0869-2084-2022-67-6-345-349(in Russian).
  51. BazarnyyVV, SidenkovaAP, RezaikinAV, MyakotnykhVS, SelkinaEO, PolushinaLG, MaksimovaAYu, VankovaEA. The possibility of using the results of studies of oral fluid and buccal epithelium in the diagnosis of Alzheimer's disease. Advances in Gerontology. 2021;34(4):550-557. doi:10.34922/AE.2021.34.4.007(in Russian).
  52. Myakotnykh VS, Sidenkova AP, Ostapchuk ES, Kulakova IA, Belykh NA, Borovkova TA. Cognitive aging and cognitive reserve: points of contact. Advances in gerontology. 2020;33(2):256-264.doi: 10.34922/AE.2020.33.2.006 (in Russian).
  53. MelnikAA, DickKP, SerdyukOV, SidenkovaAP, RomashovaAS, KhatskevichAK, SalkovaLA, FominaAS, AgafonovaYuA. Mild cognitive decline with psychopathological symptoms (literature review). Siberian Herald of Psychiatry and Addiction Psychiatry. 2023;2(119):70-77. https:doi.org/10.26617/1810-3111-2023-2(119)-5-13 (in Russian).
  54. Chipi E, Salvadori N, Farotti L, Parnetti L. Biomarker-based signature of alzheimer's disease in pre-mci individuals. Brain Sci. 2019 Aug 23;9(9):213. doi: 10.3390/brainsci9090213. PMID: 31450744; PMCID: PMC6769621.
  55. Parnetti L, Chipi E, Salvadori N, D'Andrea K, Eusebi P. Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. Alzheimers Res Ther. 2019 Jan 15;11(1):7. doi: 10.1186/s13195-018-0459-7. PMID: 30646955; PMCID: PMC6334406.
  56. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kövari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012 May;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7. PMID: 22487856; PMCID: PMC3560290.